Last reviewed · How we verify
NCT04672590
COVID-19 Neurological Disease: A Prospective Study
trial testing Primary exposure is hypoxia (no intervention) in Diseases of the Nervous System in 1,017 participants. Completed in 31 December 2024.
31 March 2023
Quick facts
| Lead sponsor | University of Liverpool |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,017 |
| Start date | 20 April 2021 |
| Primary completion | 31 March 2023 |
| Estimated completion | 31 December 2024 |
| Sites | 5 locations across Malawi, Brazil, India |
Drugs / interventions tested
- Primary exposure is hypoxia (no intervention)
Conditions studied
- Diseases of the Nervous System — all drugs for Diseases of the Nervous System →
- Other Specified Viral Diseases — all drugs for Other Specified Viral Diseases →
Sponsor
University of Liverpool
Who can join
18 and older, any sex, with Diseases of the Nervous System or Other Specified Viral Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: Recent reports increasingly recognize neurological manifestations in COVID-19 patients. However, the full spectrum of the disease and risk factors are not well understood. Aim: To describe the full spectrum of neurological manifestations in COVID-19 and assess the clinical characteristics, risks and prognostic factors. Outcomes: Identification of COVID-19 associated neurological disease is the primary outcome while requirement for admission to critical care unit, mortality, length of hospital stay, quality of life, and neurological disability are the secondary outcomes. Participants: Patients above Age more than 18 years enrolled based on new-onset acute neurological disease and COVID19 positive will serve as cases while patient with confirmed COVID-19 without neurological manifestation will serve as controls. Design and Procedures: The study is prospective case control in design and is divided into three phases in India, Brazil and Malawi ; the first phase will address role of hypoxia in causation of neurological diseases, the second phase will compare characteristics of patients hospitalized with COVID-19 with and without neurological disease and the third phase will assess the long-term follow up (at 3 months and 9 months) of cases.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04672590
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diseases of the Nervous System
Currently open trials in the same condition.
- NCT05013944 — AnovaOS Network Powered Patient Registry · recruiting
Other University of Liverpool trials
Trials by the same sponsor.
- NCT07368881 — Fast Food Online Delivery Purchase Behaviour in the Presence and Absence of Price-based Incentives · NA · not yet recruiting
- NCT07339982 — Supermarket Labelling and Taxation Study · NA · not yet recruiting
- NCT07423845 — Nutri-score Labels on the Nutritional Quality of Out-of-home Food Selection · NA · recruiting
- NCT07339969 — Food Choice Among Individuals With an Eating Disorder Diagnosis · NA · recruiting
- NCT07103967 — Investigating the Effects of Calorie Information and Serving Size of Alcohol Products on Alcohol Consumption. · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04672590 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Liverpool
- Last refreshed: 22 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04672590.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing